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1. Introduction 
Since the introduction of acetylsalicylic acid (aspirin) as the first nonsteroidal 
antiinflammatory drug (NSAID) in 1897, NSAIDs have been widely used in the 
management of pain and inflammation (Botting, 2010; Vane et al., 1990; Wallace, 1997). 
Today, they are classified as traditional nonsteroidal antiinflammatory drugs (tNSAIDs), 
characterized by differing degrees of antiinflammatory, analgesic and antipyretic activity. 
tNSAIDs are among the most widely used medicines in the world. Unfortunately, they are 
associated with dose-dependent gastrointestinal (GI) adverse events ranging from 
dyspepsia (10-20%) to symptomatic and complicated ulcers (1-4%) (Scheiman, 2006; Wolfe et 
al., 1999). The mechanism of tNSAIDs action is attributed to the cyclooxygenase (COX) 
inhibition (Botting, 2010; Vane, 1971). Cyclooxygenase is a key rate-limiting enzyme that 
exists in at least two isoforms: COX-1 is observed constitutively expressed in various tissues, 
whereas COX-2 does not appear to be expressed except at very low levels in most tissues 
and is rapidly upregulated in response to growth factors and cytokines. More recently, 
COX-2 has been implicated in several distinct cellular mechanisms, such as angiogenesis, 
proliferation and the prevention of apoptosis (Dempke et al., 2001). New antiinflammatory 
drugs have been synthesized, such as selective COX-2 inhibitors (anti-COX-2), however, 
these drugs may present side effects, such as the ability to modify the epithelial barrier. 
Inflammatory bowel disease (IBD) is a common chronic gastrointestinal disorder 
characterized by alternating periods of remission and active intestinal inflammation.  
The precise etiology of IBD, including Crohn´s disease (CD) and ulcerative colitis (UC), 
remains unclear. However, environmental factors, immunological disturbances, genetic 
influences and the presence of certain chemical mediators (cytokines) have been established 
as putative participants in the pathogenesis of the disease (Barbieri, 2000; Lashner, 1995; 
Podolsky, 2002). 
In the last few decades, the development of experimental models for studying IBD has 
greatly contributed to enhance understanding of the immunological mechanisms involved, 
such as changes in the gut epithelial barrier (Colpaert et al, 2001; Shorter et al, 1972). IBD 
seems to occur when luminal antigens from the bacterial flora stimulate the immune system 
www.intechopen.com
 
Inflammatory Bowel Disease – Advances in Pathogenesis and Management 
 
4 
in the gut barrier towards an exacerbated, genetically defined response. Patients present an 
increase in the amount of intestinal bacterial antigen compared to healthy individuals 
(Bonen & Cho, 2003). In particular, some human and animal studies have shown the prime 
importance of gut epithelial barrier integrity and changes that lead to deregulation of the 
immune system as a result of the loss of intestinal homeostasis (Élson et al., 1995). 
A possible association between the use of NSAIDs and the relapse of IBD has been 
repeatedly suggested. IBD patients seek relief in NSAIDs for non-IBD-related pains 
(arthralgias, arthritides) and these drugs are also prescribed for the symptons of 
extraintestinal manifestations of IBD, such as peripheral arthritis, sacroiliitis, ankylosing 
spondylitis, and osteoporosis-related fractures. NSAIDs are considered to be the first-line 
treatment for the abnormalities just mentioned (i.e, relieve pain and treat inflammation).  
It has been reported that CD is associated with gut barrier dysfunction and that some 
patients express an instestinal barrier hyperresponsiveness to NSAIDs (Gornet et al., 2002). 
Thus, clinicians are concerned that the treatment with NSAIDs could increase the risk of 
disease aggravation relapse in controlled patients. A large number of people suffering from 
IBD take NSAIDs and COX-2 inhibitors for various reasons, as the efficiency of these drugs 
in pain control seems to be unquestioned. In some patients, exacerbation disease happens; 
however it is uncertain whether NSAIDs are implicated in IBD relapse or whether COX-2 
inhibitors are safer than NSAIDs.  
NSAIDs have been implicated in the onset or the exacerbation of IBD in a number of studies 
and case reports, whereas in other studies, no relationship has been found between NSAID 
treatment and an increase in significant disease flares. On the other hand, COX-2 inhibitors 
have a smaller incidence of toxicity to the small bowel or colon, as recent studies indicate 
that COX-2 inhibitors are prescribed more often than NSAIDs in patients who are older, 
sicker, and have risk factors associated with NSAID gastropathy (Bonner et al., 2000; Bonner 
et al., 2004; Kurahara et al, 2001; Vane et al., 1998). Is the concept that the use of NSAIDs is 
associated with relapse of IBD is true? For this reason, many studies are conducted with the 
use of COX-2 in experimental models. So, the objective of this review is to describe the role 
of COX-2 inhibitors on different experimental models of colitis. 
2. COX-1/ COX-2 concept, biochemistry and structural comparisons 
Cyclooxygenase (COX) or prostaglandin H2 synthase (PGHs) is the enzyme that catalyzes 
the first two steps in the biosynthesis of the prostaglandins (PGs) from the substrate 
arachidonic acid (AA). These are the oxidation of AA to the hydorxyendoperoxide PGH2. 
The PGH2 is transformed by a range of enzymes and nonenzymic mechanisms into the 
primary prostanoids, PGD2, PGE2, PGF2┙, PGI2 and thromboxane A2 (TXA2) (DeWitt & 
Smith , 1988) (Figure 1). 
COX activity has long been studied in preprarations from sheep seminal visicles, and this 
enzyme was cloned by three separate groups in 1988 (DeWitt & Smith , 1988; Merlie et al, 
1988; Yokoyama et al., 1988;). The discovery of a second form of COX in the early 1990s was 
the most important event in prostanoid biology in almost 20 years. Induction of this isoform, 
COX-2, by several stimuli associated with cell activation and inflammation assured the 
relevance of this finding to inflammatory disease in general. A clear sign of the therapeutic 
value of this discovery is that in the relatively short time of about five years, several highly 
effective anti-inflammatory agents and new therapeutic areas have become subjects for 
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investigation (Bakhle & Botting, 1996; Botting, 2010; Herschman, 1996; Jouzeau et al., 1997; 
Luong et al., 1996).  
 
 
Fig. 1. The arachidonic acid cascade. 
The inducible enzyme COX-2 is very similar in structure and catalytic activity to the 
constitutive COX-1. The biosynthetic activity of both isoforms can be inhibited by aspirin 
and other NSAIDs (Botting, 2010; Vane, 1971). Both isoforms have a molecular weight of  
71 K and are almost identical in length, with just over 600 aminoacids, of which 63% are  
in an identical sequence. However, the human COX-2 gene at 8.3 kb is a small immediate 
early gene, whereas human COX-1 originates from a much larger 22-kb gene. The gene 
products also differ, with the mRNA for the inducible enzyme being approximately 4.5 kb 
and that of the constitutive enzyme being 2.8 kb (Bakhle & Botting, 1996; Botting, 2010; 
Jouzeau et al., 1997). 
The three-dimensional X-ray crystal structure of human or murine COX-2 (Mancini et al, 
1994; Picot etal., 1994) can be superimposed on that COX-1 (Lecomte et al., 1994); the 
residues that form the substrate binding channel, the catalytic sites, and the residues 
immediately adjacent are all identical except for two small variations. In these two positions, 
the same substitutions occur: Ile in COX-1 is exchanged for Val in COX-2 at positions  
434 and 523 (the residues in COX-2 are given the same number as their equivalent 
aminoacids in COX-1). 
In spite of this structural identify, there are clear biochemical differences between the 
isoforms in substrate  and inhibitor selectivity. For example, COX-2 will accept a wider 
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range of fatty acids as substrates than will COX-1 (Bakhle & Botting, 1996; Botting, 2010). 
Thus, although both enzymes can utilize AA and dihomo-┛-linolenate equally well, COX-2 
oxygenates other fatty acid substrates, such as eicosapentaenoic acid, ┛-linolenic acid, ┙-
linolenic acid, and linoleic acid more efficiently than does COX-1. Also, COX-2 acetylated by 
aspirin on Ser 530 will still oxidize AA but to 15-HETE, whereas similarly acetylated COX-1 
will not oxidize AA at all (Griswold & Adams, 1996; O’Neill et al., 1994; Wong et al., 1997). 
In addition (see below), inhibitors will differentiate between COX-2 and COX-1 with over 
1000-fold selectivity (Gierse et al., 1996; Luong  et al., 1996). 
Supporting evidence is strongest from the work on COX-2-selective inhibitors; mutation of 
Ile 523 to Val in the COX-1 protein allows COX-2-selective inhibitors to bind and inhibit 
PGH2 formation without altering the Km  for AA (Guo et al., 1996), and the reverse mutant of 
COX-2 in which Val 523 is exchanged for Ile shows inhibitor binding and selectivity profiles 
comparable to those of wild-type COX-1 (Bhattacharyya et al., 1996; Mancini et al., 1995). 
The structural basis for this has been shown clearly in the crystal analyses of COX-2, which 
have used either the human or the murine protein, each bound to a nonselective COX-1 or 
COX-2 inhibitor. The smaller size of Val 523 allows the inhibitor access to a side pocket off 
the main substrate channel in COX-2-access that is denied sterically by the longer side chain 
of Ile in COX-1. Selective inhibitors of COX-2 do not bind to Arg 120, which is used by the 
carboxylic acid ot the substrate AA and by the COX-1-selective or-nonselective NSAIDs, all 
of which are carboxylic acids (Ren et al., 1995a; Ren et al., 1995b).  
Another striking structural difference between the isoforms, but of unknown significance, is 
the absence of a sequence of 17 amino acids from the N terminus and the insertion of a 
sequence of 18 amino acids at the C terminus of COX-2 i comparison to COX-1. This 
accounts for the different numbering for the analogous residues in the two isoforms (e.g. the 
acetylatable serine is Ser 530  in COX-1 but Ser 516 in COX-2). The C-terminal insert in COX-
2 does not alter the last four amino acids residues, which in both proteins form the signal for 
attachment to the membrane of the endoplasmic reticulum (ER). However, COX-2 is located 
on the nuclear membrane as well as on the ER, while COX-1 is found attached only to the 
membranes of the ER. The reason for this selective localization may lie in the different 
sequence of the C terminus. It is relevant that in the X-ray structural analysis of either 
isoform, the three-dimensional structures of the last 18 C-terminal residues in COX-1 and 
the last 30 residues in COX-2 were not resolved, implying a marked flexibility in this region 
of the proteins even in the crystalline form (Hudson et al., 1993; Mitchell et al., 1993; Morita 
et al., 1995; Otto & Smith, 1994; Regier et al., 1993). Although emphasis has been placed here 
on the differences between isorforms, the extensive overall structural and biochemical 
similarity between COX-1 and COX-2 must be reiterated. Both use the same endogenous 
substrate, AA, and form the same product by the same catalytic mechanism. Their major 
difference lies in their pathophysiological functions. 
2.1 Physiological and pathological functions of COX-1 and COX-2 
Chronic inflammation is an excellent example of a disease that represents a malfunction of 
normal host defense systems. Thus, rather than classifying PG biosynthesis into 
physiological and pathological, it may be better to use the classification applied to the COX 
isoforms: either constitutive or induced. COX-1 activity is constitutive, present in nearly all 
cell types at a constant level; COX-2 activity is normally absent from cells, and when 
induced, the protein levels increase and decrease in a matter of hours after a single stimulus 
(Bakhle & Botting, 1996; Botting, 2010; Jouzeau et al., 1997). 
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The main reason for labeling COX-1 and COX-2 as physiological and pathological, 
respectively, is that most of the stimuli known to induce COX-2 are those associated with 
inflammation, for example, bacterial lipopolysaccharide (LPS) and cytokines such as 
interleukin (IL)-1, IL-2, and tumor necrosis factor alpha (TNF-┙). The anti-inflammatory 
cytokines, IL-4, IL-10, and IL-13, will decrease induction of COX-2, as will the corticosteroids 
(Bakhle & Botting, 1996; Luong et al., 1996). The physiological roles of COX-1 have been 
deduced from the deleterious side effects of NSAIDs, which while inhibiting PG 
biosynthesis at inflammatory sites, also inhibit constitutive biosynthesis. Thus, COX-1 
provides PGs in the stomach and intestine to maintain the integrity of the mucosal 
epithelium and its inhibition leads to gastric damage, hemorrhage and ulceration. 
2.2 Mechanisms of NSAID injury to the gastrointestinal mucosa 
For evaluation of the validity of new potentially less toxic NSAIDs it is mandatory to clearly 
understand the pathogenesis of NSAID induced ulceration (Figure 2). Both aspirin and non-
aspirin NSAIDs inhibit the COX pathway of prostaglandin synthesis (Botting, 2010; Hudson 
et al., 1993; Mitchell et al., 1993; Vane, 1971). This represents the basis of anti-inflammatory 
action but is also responsible for the development of side effects in the gastrointestinal tract 
and kidney as well as inhibition of platelet aggregation. Inhibition of prostaglandin 
synthesis can exert injurious actions on the gastric and duodenal mucosa as it abrogates a 
number of prostaglandin dependent defence mechanisms. Inhibition of COX leads to a 
decrease in mucus and bicarbonate secretion, reduces mucosal blood flow, and causes 
vascular injury, leucocyte accumulation, and reduced cell turnover, all factors that 
contribute to the genesis of mucosal damage. Within this broad spectrum of events, the 
microvascular damage appears to play a central role. Prostaglandins of the E and I series are 
potent vasodilators that are continuously produced by the vascular endothelium. Inhibition 
of their synthesis by an NSAID leads to vasoconstriction (Gana et al., 1987). Furthermore, 
inhibition of prostaglandin formation results in a rapid and significant increase in the 
number of neutrophils adhering to the vascular endothelium in both gastric and mesenteric 
venules (Asako et al., 1992 a;b; Wallace et al., 1993). Adherence is dependent on expression 
of the â2 integrin (CD11/CD18) on neutrophils and intercellular adhesion molecule on the 
vascular endothelium (Wallace et al., 1993).  Neutrophil adherence in turn causes 
microvascular stasis and mucosal injury through ischaemia and release of oxygen derived 
free radicals and proteases (Vaananen et al., 1991).  
The severity of experimental NSAID gastropathy was markedly reduced in rats rendered 
neutropenic by pretreatment with antineutrophil serum or methotrexate (Lee et al., 1992; 
Wallace et al., 1990) Recently, Wallace et al (2000) provided evidence for an isoenzyme 
specific role of COX in the homeostasis of the gastrointestinal microcirculation. Thus in rats, 
the selective COX-1 inhibitor SC-560 decreased gastric mucosal blood flow without affecting 
leucocyte adherence to mesenteric venules. In contrast, the selective COX-2 inhibitor 
celecoxib markedly increased leucocyte adherence but did not reduce gastric mucosal blood 
flow. Only concurrent treatment with the COX-1 and COX-2 inhibitor damaged the gastric 
mucosa, suggesting that reduction of mucosal blood flow and increase in leucocyte adhesion 
have to occur simultaneously to interfere with mucosal defence. Inhibition of prostaglandin 
synthesis thus plays a key role in induction of mucosal injury but does not represent the 
only pathway by which NSAIDs can damage the gastrointestinal mucosa. NSAIDs can also 
induce local damage at the site of their contact with the gastrointestinal mucosa. Topical 
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application of NSAIDs increases gastrointestinal permeability allowing luminal aggressive 
factors access to the mucosa. Aspirin and most non-aspirin NSAIDs are weak organic acids. 
In the acidic milieu of the stomach, they are converted into more lipid soluble unionised 
acids that penetrate into the gastric epithelial cells. There, at neutral pH, they are reionised 
and trapped within the cell causing local injury. Having entered gastric mucosal epithelial 
cells, NSAIDs uncouple mitochondrial oxidative phosphorylation. This effect is associated 
with changes in mitochondrial morphology and a decrease in intracellular ATP and 
therefore a reduced ability to regulate normal cellular functions such as maintenance of 
intracellular pH. This in turn causes loss of cytoskeletal control over tight junctions and 
increased mucosal permeability. The ability of NSAIDs to uncouple oxidative 
phosphorylation stems from the extreme lipid solubility and position of a carboxyl group 
that acts as a proton translator (Mahmud et al., 1996; Somasundaram et al., 2000).  A further 
mechanism involved in the topical irritant properties of NSAIDs is their ability to decrease 
the hydrophobicity of the mucus gel layer of the gastric mucosa.  NSAIDs can convert the 
mucus gel from a non-wettable to a wettable state and in experimental animals this effect 
has been shown to persist for several weeks or months after discontinuation of NSAID 
administration. Gastric mucosal lesions can also occur in a non-acidic milieu, such as 
following rectal application. With oral administration, gastric acid however appears to 
enhance NSAID induced damage. More extensive and deeper erosions occur at low pH and 
an elevation in gastric pH above 4 is necessary to prevent this acid related component. 
Prostaglandins do not represent a unique pathway to protect the gastric mucosa. Nitric 
oxide (NO) has the potential to counteract potentially noxious effects of inhibition of  
 
 
Fig. 2. Pathogenesis of NSAID-induced intestinal lesions (Taken from Thiéfin &  
Beaugerie, 2005). 
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prostaglandin synthesis, such as reduced gastric mucosal blood flow and increased 
adherence of neutrophils to the vascular endothelium of the gastric microcirculation. NO 
has well characterised inhibitory effects on neutrophil activation/adherence demonstrated 
in various tissues. 
2.3 Chronic inflammatory bowel disease and COX-2 
The potential role for prostaglandins in the inflammatory process underlying chronic IBD 
has been a focus of controversy. Under the hypothesis that prostaglandins may be 
protective, treatment with exogenous prostaglandins was investigated but found to 
exacerbate the diarrhea. The possibility that proinflammatory mechanisms might be 
involved prompted trials of NSAID therapy. However, studies of various NSAIDs in 
patients with ulcerative colitis showed either no improvement or an exacerbation of the 
symptoms (Rampton & Sladen, 1981). In keeping with these early findings, some reports 
suggested a deleterious effect of NSAIDs on the course of IBD (Evans et al., 1997; Felder et 
al., 2000). The magnitude of the risk, however, remains controversial (Bonner et al., 2002; 
Nion-Lamurier et al., 2003). The recent review article meets different studies including 
original papers, case reports, reviews, controlled trials and databases about exacerbation of 
IBD associated with the use of NSAIDs (Kefalakes et al., 2009). The Table 1 showed the 
mechanisms of action of NSAIDs and COX-2 inhibitors in patients with IBD.  
2.4 Development of the “COXIBs” 
The identification of the COX-2 isoenzyme opened the door to development of NSAIDs 
which selectivity inhibit COX-2. The main goal of which was to decrease the GI toxicity. The 
first generation of selective COX-2 inhibitors came from animal models in which 
compounds were sought that were potent anti-inflammatory agents with minimal side 
effects on the stomach (Nimesulide, etodolac and meloxicam) (Carvalho et al., 2004). The 
discovery of the specificity these products was in reality found after the sale, being due, 
mainly on clinical and experimental observations reduced incidence of gastrointestinal side 
effects, and subsequently confirmed by in vitro studies. The nimesulide is considered an 
aberrant example of NSAIDs, with good power in vivo inflammatory models, but with 
weak inhibition in vitro preparations of COX. The nimesulide and display specificity of 
action on COX-2, has other effects that further enhance their anti-inflammatory activity, as 
inhibition of neutrophil activation and antioxidant properties. Based on in vitro studies 
initially suggested that meloxicam selectively inhibited COX-2. However, when tested in 
vivo, in humans, its specificity for COX-2 was only about ten times higher than that for COX-
1, with further platelet inhibition (Panara et al., 1999). The molecular modification of these 
drugs, especially those of nimesulide, in order to increase its COX-2 selectivity, resulted in 
structures without a carboxylic group and the presence of a sulphonamide or sulphone 
group, resulting specific inhibitors in the second generation. This group includes celecoxib, 
rofecoxib, valdecoxib, parecoxib (pro-drug of valdecoxib), APHS [o-(acetoxyphenyl)hept-2-
ynyl sulfide] and etoricoxib (Fitzgerald & Patrono, 2001; Kulkarni et al., 2000). 
Coxib spare COX-1 and firstly inhibit COX-2 function therefore decrease but do not 
eliminate NSAIDs associated GI toxicity and are efficacious as tNSAIDs in relieving pain. 
Data from large GI outcomes studies have characterised the GI effects of coxib. The 
Celecoxib Longterm Arthritis Safety Study (CLASS Study) that compared high dose 
Celecoxib (400 mg bid), diclofenac (75 mg bid), and ibuprofen (800 mg 3 times daily) 
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showed that symptomatic ulcers were significantly less common among celecoxib users 
than tNSAIDs users; however ulcer complication rates were not significantly different 
(which was probably due to the confounding factor of concomitant low-dose aspirin use 
which was present in 22% of patients) (Silverstein et al., 2000). However, a recent meta-
analysis of available trials of the Cochrane collaboration confirms that celecoxib at any 
dosewas associated with statistically less GI events (Moore et al., 2005). Moreover, the 
results of another large outcomes study, celecoxib vs naproxen and diclofenac in 
osteoarthritis patients (SUCCESS I Study), confirmed the significantly better safety profile of 
celecoxib compared with tNSAIDs (Singh et al., 2006). The Vioxx Gastrointestinal Safety of 
Rofecoxib trial (VIGOR Study) concluded that rofecoxib users had 50% fewer GI events 
compared with naproxen users (Bombardier et al., 2000). Later, in the comparison of 
lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and  
 
Drug Mechanism of action 
Conventional NSAIDs COX-1 and COX-2 } PGE reduction 
 Surface membrane phospholipid interaction 
 Effect on mitochondrial energy metabolism 
 (oxydase phosphorilation inhibition } ATP 
deficiency } | mucosal permeability) 
 Escalation of intestinal inflammatory activity 
 Enhancement of enterohepatic circulation 
 Formation of drug enterocyte adducts 
 COX-independent damage to the small 
intestine 
 Small-bowel enteropathy } blood loss } 
hypoalbuminemia 
 | TNF-┙, IL-1, NO release 
 Lower the thromboxane production 
 
COX-1 inhibitors Impairs mucosal microcirculatory blood flow 
 Lower the thromboxane production 
 Impairs mucous secretion and acid regulation 
 Impair renal blood flow and platelet 
aggregation 
 
COX-2 inhibitors Imunomodulatory and anti-inflammatory role 
on the GI tract (selective COX-2 inhibition } 
PGE reduction) 
 Loss of vasodilation 
 Increased of vascular permeability 
 May delay epithelial proliferation 
 Delay wound healing 
 | Oxygen metabolites (LTB4, TNF) 
 | Leukocyte adherence to the vascular  
endothelium 
Table 1. Mechanisms of action of NSAIDs and COX-2 inhibitors in patients with IBD (Taken 
from Kefalakes et al., 2009). 
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Gastrointestinal Event Trial (TARGET), showed a 75% decrease in adverse GI events with 
the coxib (Schnitzer et al., 2004). It is important to emphasise that although the incidence of 
adverse GI events increased in relation to the presence of GI risk factors, the differences 
from NSAIDs were maintained in subgroups of patients with and without risk factors 
(Skelly et al., 2003). 
The lumiracoxib is a novel highly selective COX-2 inhibitor. Lumiracoxib differs structurally 
from others drugs in the class of selective COX-2 inhibitors (Figure 3) (Brune & Hinz 2004; 
Mangold et al., 2004). Differently, the lumiracoxib is a phenyl acetic acid derivative. It has 
the highest selectivity (selective for COX-2 compared with COX-1 in the human whole blood 
assay with a ratio of 515:1 in healthy subjects and a fairly short plasm half-life (3-6 hours) 
compared with other COX-2 selective inhibitors (Esser et al., 2005).  In endoscopic studies, 
lumiracoxib has been associated with a rate of acute gastric injury and chronic ulcer 
formation that does not differ form placebo (Rordorf et al., 2003) and which was 
significantly lower than with the NSAID ibuprofen and with celecoxib (Hawkey et al., 2004; 
Kivitz et al 2004). 
Notwithstanding, it is important to note that 3 of the above commented outcome studies 
(CLASS, TARGET and SUCCESS studies) (Schnitzer et al., 2004; Silverstein et al., 2000; 
Singh et al., 2006), one endoscopy study (Solomon et al., 2005) and several 
epidemiological studies (Lanas et al., 2005) have shown that the concomitant use of low-
dose aspirin and coxib or tNSAIDs increases further the risk of upper GI bleeding in 
NSAIDs users and attenuates the GI advantage of a coxib over an tNSAID.A recent meta-
analysis of RCTs has shown that coxib plus low-dose ASA use was associated with a 
lower risk of upper GI complications when compared to non-selective NSAID plus low-
dose ASA (Rostom et al., 2009). These gastrointestinal benefits have to be balanced against 
the known cardiovascular risks, particularly with long-term use. The VIGOR and 
Adenomatous Polyp Prevention on Vioxx Trial Investigators (APPROVe) studies showed 
that rofecoxib were associated with increased risk of cardiovascular events after 12 and 36 
months of treatment when compared to naproxen (VIGOR) or placebo (APPROVe) 
(Bombardier et al., 2000; Bresalier et al., 2005). Other outcome studies have shown also 
that celecoxib at doses of 400 mgbid or 200 mgbid (Laine et al., 2004), but not 400 mg once 
a day (Arber et al., 2006) is associated with increased risk of cardiovascular events. 
Observational studies have shown, however, that celecoxib at 200 mg/day dose was not 
associated with increased risk of cardiovascular events (Bombardier et al., 2000; 
Silverstein et al., 2000). Recent observational studies have shown that also most NSAIDs 
(including nonselective) may be associated with increased cardiovascular risk and this 
may be different for the different compounds, dose and length of treatment (Chan et al., 
2006; Lanas et al., 2005; McHippisley-Cox & Coupland, 2005). Of all traditional NSAIDs, 
diclofenac have been found to be the one increasing the CV risk the most (Mc Gettigan & 
Henry, 2006). In the MEDAL program etoricoxib at the dose of 60–90 mg/day was found 
to be not different to diclofenac in the incidence of CV events (Cannon et al., 2006). The 
study also showed no differences in the incidence of upper GI complications between 
these 2 compounds, although the total number of events (symptomatic ulcers and 
complications) was statistically lower in etoricoxib users (Laine et al, 2007). Lastly, both 
tNSAIDs and coxib may also increase blood pressure and reduce kidney function. 
Following, we describe the effects of these COX-2 inhibitors on differents studies on 
experimental colitis models. 
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Fig. 3. The chemical structures of some COX-2 inhibitors. 
2.5 COX-2 inhibitors on experimental colitis models 
The role of selective inhibition of COX-2 for the inflammatory process and the course of 
experimental and human colitis is controversially discussed, even though increased levels of 
prostaglandins (PGE2 and PGI2) and other eicosanoids were detected in both colitis models 
and patients with chronic inflammatory bowel disease, which correlates well with the 
disease activity. PGE2 is produced by mononuclear cells in the lamina propria and is 
dependent on COX-2 expresion. It modulates the intestinal immune response, including the 
differentiation of T cells and the production and release of proinflammatory cytokines. 
During the course of inflammatory bowel disease and experimental colitis, some 
prostanoids are released and subsequently modulate the course of the disease.  
Animal models are used extensively to study the pathogenesis and pathophysiology of IBD 
and to evaluate therapies. The more extensively used models were: acetic acid colitis, 
dextran sodium sulphate (DSS) and 2,4,6’-trinitrobenzene sulphonic acid (TNBS). Acetic-
acid-induced colitis in rats resembles human ulcerative colitis in histology, eicosanoid 
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production and excessive oxygen-derived free radicals release by inflamed mucosa (Millar 
et al., 1996). DSS-induced ulcerative colitis is accompanied by erosion and ulceration as well 
as inflammatory cell infiltration, characteristics resembling those of human ulcerative colitis 
(Okayama et al., 2007). TNBS-induced colitis is accompanied by marked thickening of the 
colonic wall, infiltration of polymorphonuclear leukocytes and ulceration, resembling the 
human Crohn´s disease (Morris et al., 1989).  A number of animal studies have reported the 
positive effect of COX-2 inhibition, others exacerbation of colitis (Table 2). 
 
Study Model of colitis Drug Results 
Reuter et al. (1996) TNBS diclofenac (10mg/kg) 
naproxen (5mg/kg) 
etodolac (10 or 50mg/kg) 
nabumetone (25 or 75mg/kg)
L745,337 (1 or 5mg/kg) 
 
unfavorable 
Lesch et al. (1999) TNBS NS-398*
SC-58125* 
PD-138387* 
*dose of 100mg/kg 
 
unfavorable 
Karmeli et al. (2000) Acetic-acid or 
iodoacetamide 
nimesulide (10mg/kg)
SC-236 (6mg/kg) 
 
favorable 
Cuzzocrea et al. (2001) DNBS celecoxib (5mg/kg)
 
favorable 
Martin et al. (2003) TNBS rofecoxib
 
favorable 
Martin et al. (2005) DSS Rofecoxib (2.5-10mg/kg)
 
favorable 
Singh et al. (2003) Acetic-acid; 
LTB4-induced IBD) 
 
nimesulide (9 and 18mg/kg)
 
favorable 
Zhang et al. (2004) TNBS celecoxib (1.25mg/kg)
 
unfavorable 
El-Medany et al. (2005) Acetic-acid celecoxib (5mg/kg)
rofecoxib (2.5mg/kg) 
favorable 
Kruschewski et al. (2006) TNBS NS-398 (10mg/kg)
 
favorable 
Tsubouchi et al. (2006) DSS rofecoxib
 
unfavorable 
Dudhgaonkar et al. (2007) TNBS rofecoxib (10mg/kg)
 
favorable 
Okayama et al. (2007) DSS celecoxib (3mg/kg)
 
unfavorable 
Paiotti et al. (2009) TNBS lumiracoxib (6mg/kg)
 
unfavorable 
 
Table 2. COX-2 inhibitors on experimental colitis. 
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Karmeli et al. (2000) reported that nimesulide, ameliorates the extent of tissue damage in 
acetic acid and iodoacetamide-treated rats. The decrease in the extent of colitis induced by 
nimesulide was accompanied by a significant decrease in mucosal MPO and nitric oxide 
synthase (NOS) activities. 
There is good evidence that an enhanced formation of reactive oxygen species contributes 
to the pathophysiology of IBD (Guo et al., 1999; Kruidenier & Verspaget, 2002). 
Quantitatively, the principal free radical in tissues is superoxide anion (O2¯), which is 
converted to H2O2 by superoxide dismutase. Superoxide anion (O2¯) can be produced by 
activated neutrophils through NADPH oxidase, which reduces molecular oxygen to the 
O2¯ radical through the enzyme myeloperoxidase. Nitric oxide (NO), a reactive free 
radical gas, is generated enzymatically in a variety of cells from the L-arginine pathway 
by three isoforms of NO synthetase (Yue et al., 2001). In the GI tract, NO can be either 
protective or damaging to tissues, depending on what type of NOS is involved in the 
pathological condition. In experimental colitis, NO derived from  iNOS, together with 
other free radicals, contribute significantly to the inflammatory response in the colon. The 
mechanism for this inflammatory response is likely explained by the interaction of NO 
with superoxide to produce peroxynitrite, which is a strong oxidizing agent that  initiates 
lipid peroxidation (El-Medany et al., 2005). Combination of rofecoxib and aminoguanidine 
hydrochloride has protective effect on colonic injury by TNBS which is probably, via 
mechanism of local inhibition of iNOS and COX-2 activity in colonic mucosa 
(Dudhgaonkar et al., 2007).  
Cuzzocrea et al. (2001) have provided evidence for the potential protective effect of 
celecoxib in reducing the severity of colonic injury induced by dinitrobenzene sulfonic acid 
(DNBS). They observed reduction of the degree of colonic injury, the MPO activity, 
hemorrhagic diarrhoea and the weight loss. Martin et al. (2003; 2005) have demonstrated 
that rofecoxib seems to have beneficial effects in TNBS-induced colitis in rats and in acute 
DSS-induced colitis in mice; probably by the initial diminishing the initial stage of 
inflammation by a mechanism related to inhibition of PGE2 by the COX-2 pathway as well 
by reducing neutrophil infiltration and inhibiting up-regulation of IL-1┚. The use of 
nimesulide in two different models (acetic acid -and LTB4-induced IBD) significantly 
prevented development of inflammatory changes, decreased MPO activity, and also 
restored the altered contractility response of the isolated colon segment  (Singh et al., 2003). 
In addition, El-Medany et al. (2005) showed that treatment with the celecoxib and rofecoxib 
reduced the inflammation and subsequent tissue damage to the colon induced by acetic 
acid, as verified by macroscopic, histological and biochemical findings. They demonstrated 
that these drugs exert a significant attenuation of the extent and severity of the histological 
signs of cell damage, significant reduction in tissue PGE2 production, as well reduction in 
NOS activity.  
The acute phase of TNBS colitis is characterized by a significant reduction of capillary blood 
flow, capillary density, diuresis, and weight and a significant increase in capillary 
permeability, leukocyte sticking, and hematocrit (Kruschewski et al., 2006). Kruschewski et 
al. (2006) demonstrated that the selective COX-2 inhibitor NS-398 leads to a significant 
improvement of all microcirculatory parameters and clinical findings compared to the 
(untreated) colitis.  
 On the other hand, Reuter et al. (1996) reported that administration of three types of 
COX-2 inhibitors with moderate to high selectivity significantly exacerbated the severity 
of colonic damage in experimental colitis. Continued twice-daily administration of these 
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compounds for one week resulted in perforation of the colon, leading to death in a 
substancial number of the animals. Lesch et al. (1999) evaluated three highly selective 
COX-2 inhibitors (NS-398, SC-58125 and PD-138387) on TNBS-induced colitis and 
observed that these three compounds do not seem to have any beneficial effect in this 
model. Zhang et al. (2004) showed that celecoxib resulted in exacerbation of 
inflammation-associated with colonic damage and even led to perforation, megacolon and 
death of the rats, with the mortality rate reaching 50%. Tsubouch et al. (2006) 
demonstrated that daily administration of indomethacin and rofecoxib significantly 
delayed the healing of colitis with deleterious influences on histological restitu as well as 
mucosal inflammation. Okayama et al. (2007) showed that celecoxib aggravated the 
severity of colonic ulceration and inflammation, as represented by the gross injury and 
the shortening of colon length as well as the myeloperoxidase activity (MPO) on dextran 
sulfate sodium (DSS) induced colitis.  
Although lumiracoxib interacts with the COX-2 enzyme via mechanisms different from 
other COX-2 selective inhibitors and is associated with improved gastrointestinal 
tolerability, Paiotti et al. (2009) showed this did not reduce inflammation-associated colonic 
injury in TNBS-induced colitis. They demonstrated that macroscopic and the 
histopathological assessment on the TNBS nontreated induced-colitis and lumiracoxib-
treated induced-colitis were similar. 
3. Conclusion 
The ability of selective COX-2 inhibitors to significantly exacerbate colonic injury in 
differents models of colitis suggests that prostaglandins derived from COX-2 are beneficial 
in the setting of colonic inflammation. There is a strong body of evidence to suggest that 
prostaglandins do exert anti-inflammatory and mucosal protective effects in experimental 
colitis. It is known that PGE2 inhibits inflammatory cytokines and stimulates mucus 
secretion in the GI mucosa through activation of EP4 receptors (Kabashima et al., 2002; Nitta 
et al., 2002). Nitta et al reported that a selective EP4 agonist decreased the levels of IL-1┚ and 
cytokine-induced neutrophil chemoattractant in the colorectal mucosa with marked 
downregulation of the corresponding cytokine mRNA expression. They also found that the 
IL-10 concentration was higher following administration of the EP4 agonist. These findings 
may suggest that endogenous PGE2 ameliorates the severity of dextran sodium sulphate 
colitis (DSS), presumably by suppressing the induction of proinflammatory cytokines. 
Prostaglandins are capable of reducing  the production of reactive oxygen metabolites and a 
number of inflammatory mediators suggested to contribute to the pathogenesis of human 
and experimental colitis, included leukotriene B4 and TNF-┙. In addition prostaglandins 
increase the secretion of water and electrolytes into the intestinal tract and in the acute stage 
of UC and CD, activated monocytes promote the increased concentration of PG in the 
enteric mucosa, which in turn suppresses the effect of the Na+, Ka+-ATP enzyme and 
prevents the reabsorption of  Na+, resulting in diarrhea. Some studies demonstrated that 
pretreatment with intraluminal PGE analogs (e.g. 16,16’-dimethyl PGE2) caused a reduction 
in the severity of injury induced by TNBS and acetic acid (Feng et al., 1993; Nitta et al., 2002; 
Sasaki et al., 2000 Tso et al., 1995). 
In conclusion, the relative role of  COX-2 selective inhibitors on human and experimental 
colitis to be explored. Thus, the use of COX-2 inhibitors in IBD should be considered with 
caution. 
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